GSB Wealth Management LLC Sells 489 Shares of Becton, Dickinson and Company $BDX

GSB Wealth Management LLC reduced its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 12.7% during the second quarter, Holdings Channel reports. The institutional investor owned 3,349 shares of the medical instruments supplier’s stock after selling 489 shares during the quarter. GSB Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $577,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Bfsg LLC boosted its holdings in shares of Becton, Dickinson and Company by 4.4% during the second quarter. Bfsg LLC now owns 26,071 shares of the medical instruments supplier’s stock worth $4,491,000 after purchasing an additional 1,107 shares during the period. Cardinal Capital Management lifted its holdings in Becton, Dickinson and Company by 4.4% in the second quarter. Cardinal Capital Management now owns 31,342 shares of the medical instruments supplier’s stock worth $5,399,000 after buying an additional 1,313 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. lifted its holdings in Becton, Dickinson and Company by 9.5% in the second quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,957 shares of the medical instruments supplier’s stock worth $337,000 after buying an additional 170 shares during the period. Gries Financial LLC lifted its holdings in Becton, Dickinson and Company by 118.4% in the second quarter. Gries Financial LLC now owns 7,666 shares of the medical instruments supplier’s stock worth $1,320,000 after buying an additional 4,156 shares during the period. Finally, Golden State Equity Partners boosted its position in shares of Becton, Dickinson and Company by 16.0% in the 2nd quarter. Golden State Equity Partners now owns 1,931 shares of the medical instruments supplier’s stock worth $333,000 after purchasing an additional 267 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the topic of a number of analyst reports. Argus boosted their price target on Becton, Dickinson and Company from $220.00 to $230.00 in a research report on Monday, September 15th. Wells Fargo & Company upped their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Barclays lowered their price objective on Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating on the stock in a research report on Tuesday, June 3rd. Piper Sandler reissued a “neutral” rating and set a $200.00 price target (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Finally, Morgan Stanley raised their target price on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $213.30.

Becton, Dickinson and Company Trading Down 0.2%

BDX opened at $186.74 on Tuesday. The firm has a market cap of $53.53 billion, a P/E ratio of 33.59, a P/E/G ratio of 1.51 and a beta of 0.27. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The stock has a 50-day moving average of $187.84 and a 200 day moving average of $189.61.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.51 billion during the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter last year, the firm earned $3.50 earnings per share. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s payout ratio is currently 74.82%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This represents a 19.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock valued at $551,536 in the last ninety days. Insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.